The filing is a routine insider intent-to-sell notice tied to option exercise; the small size relative to market cap and the officer's holdings suggests no material signal. Monitor for any subsequent Form 4 filings to confirm execution, but no immediate read-through for the stock.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $144.67entry
- T+1 · 13d ago +3.93%α +2.28% · $150.36
- T+5 · 7d ago +2.34%α +2.92% · $148.05
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
David Michael Williams, an officer of Merck & Co., Inc., filed a Form 144 on November 2, 2026, indicating intent to sell 21,359 shares of common stock with an approximate market value of $3.19 million. The shares were acquired via exercise of options under a registered plan on the same date, and the sale is planned for execution on the NYSE.
Key Facts
- Reporting person: David Michael Williams, an officer of Merck & Co., Inc.
- Proposed sale of 21,359 shares of common stock.
- Approximate market value of shares: $3,185,464.17.
- Shares acquired on 11/02/2026 via exercise of options under a registered plan.
- Proposed sale date: 11/02/2026.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.
- Issuer's outstanding shares: 2,467,171,638 (market cap ~$361B).
- Proposed sale represents ~0.0009% of outstanding shares and ~0.09% of the officer's reported holdings (52,847 shares held as of 08/05/2026).
Financial Impact
Proposed sale of $3.19 million in stock, representing a negligible 0.0009% of shares outstanding and about 0.09% of market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not be executed.
- Insider selling, even small, can sometimes precede broader negative sentiment, but here the amount is immaterial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010548 |
| Document: 0001950047-26-010548-index.html | 0001950047-26-010548 |
| Document: 0001950047-26-010548.txt | 0001950047-26-010548 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers